ENRICHMENT AND IDENTIFICATION OF FETAL MATERIAL
This disclosure is directed to a kit and method for retrieving a target material, such as fetal material, from a sample, such as a maternal sample or fraction thereof. An enrichment agent can be added to a vessel that contains the sample for positive selection, or, in other words, to select or aid in selecting the target material from amongst the remainder of the sample. The enrichment agent can be, for example, immunomagnetic beads, buoyant beads, high-density beads, chemicals to change the density of the target material, or the like.
1 . A method, comprising:
providing a maternal sample or a fraction thereof suspected of comprising fetal material; and
enriching the fetal material with at least two affinity molecule-enrichment agent conjugates,
wherein the at least two affinity molecules of the conjugates are directed to at least two of CD144, CD147, EPCAM, LVRN, EGFR, HLA-G, HER-2, HER-3, or HER-4, and
wherein the fetal material expresses at least one biomarker to which at least one of the at least two affinity molecules is directed.
2 . The method of claim 1 , further comprising
adding, to the maternal sample or fraction thereof, at least two affinity molecule-first complementary molecule conjugates; and
adding, to the maternal sample or fraction thereof, at least two second complementary molecule-enrichment agent conjugates,
wherein the first and second complementary molecules are binding pairs, thereby binding to or interacting with each other and forming the at least two affinity molecule-enrichment agent conjugates.
3 . The method of claim 2 , wherein the first complementary molecule is biotin and the second complementary molecule is an avidin.
4 . The method of claim 1 , wherein at least one of the at least two affinity molecule-enrichment agent conjugates, having been pre-conjugated, is added to the maternal sample or fraction thereof.
5 . The method of claim 1 , wherein the enrichment agent is immunomagnetic beads, buoyant beads, or high-density beads.
6 . The method of claim 1 , wherein the enrichment agent is immunomagnetic beads.
7 . The method of claim 6 , wherein the enriching step comprises
placing a magnet proximal to a vessel containing the maternal sample or fraction thereof,
wherein the fetal material, via the bound immunomagnetic beads, is attracted to a wall or a surface of the vessel.
8 . The method of claim 7 , further comprising removing material from the vessel that is not attracted to the wall or the surface of the vessel,
wherein the removing step is performed after the placing step.
9 . The method of claim 8 , further comprising labeling the fetal material with at least one stain.
10 . The method of claim 9 , further comprising imaging the at least one fetal material after labeling.
11 . The method of claim 10 , further comprising picking or isolating the fetal material.
12 . The method of claim 11 , further comprising sequencing the fetal material.
13 . The method of claim 11 , further comprising performing genetic testing on the fetal material.
14 . The method of claim 13 , wherein the genetic testing tests for at least one of Down's Syndrome, trisomy 18 , and neural tube defect.
15 . The method of claim 8 , further comprising
replacing the magnet proximal to the vessel,
wherein the replacing step is performed after the removing step, and
wherein the replacing step is performed after having withdrawn the magnet prior to the replacing step.
16 . The method of claim 15 , further comprising labeling the fetal material with at least one stain before the replacing step.
17 . The method of claim 16 , further comprising labeling the fetal material with at least one other stain after the replacing step.
18 . The method of claim 17 , further comprising imaging the at least one fetal material after labeling with the at least one other stain.
19 . The method of claim 18 , further comprising picking or isolating the fetal material.
20 . The method of claim 19 , further comprising sequencing the fetal material.
21 . The method of claim 19 , further comprising performing genetic testing on the fetal material.
22 . The method of claim 1 , wherein the fetal material is a fetal cell, a fetal trophoblast, fetal DNA, fetal RNA, a fetal red blood cell, or a fetal white blood cell.
23 . The method of claim 1 , wherein the enriching step further comprises a CD105-enrichment agent conjugate, and wherein the fetal material expresses at least one of the biomarkers to which the at least three affinity molecules of the conjugates are directed.
24 . The method of claim 1 , further comprising cleaving, separating, removing, or detaching the enrichment agent from the affinity molecule after the enriching step.
25 . The method of claim 24 , wherein at least one of a chemical, light, heat, or enzyme is used to induce the cleaving, separating, removing, or detaching.
26 . The method of claim 1 , wherein enriching is performed with four affinity molecule-enrichment agent conjugates, wherein the four affinity molecules of the conjugates are directed to EPCAM, LVRN, EGFR, and HER-2, and wherein the fetal material expresses at least one biomarker to which at least one of the four affinity molecules is directed.
27 . The method of claim 26 , wherein the enriching step further comprises a CD105-enrichment agent conjugate, and wherein the fetal material expresses at least one of the biomarkers to which the five affinity molecules of the conjugates are directed.